The bill amends the General Laws to ensure patient choice in the dispensing of clinician-administered drugs, which are defined as outpatient infused prescription drugs that are not self-administered and are typically given in a clinical setting. It prohibits health insurers or their third parties from refusing to authorize, approve, or pay for these drugs when administered by an in-network hospital or clinic, provided it aligns with the provider contract and the insurer's medical and payment policies. The bill also requires that the reimbursement rates to providers be negotiated and be on par with payments made to a preferred pharmacy.

Additionally, the bill tasks the office of the health insurance commissioner with conducting an analysis of the payment for clinician-administered drugs starting January 1, 2025. This analysis will include data on potentially inaccurate payments and the methodology behind reimbursement calculations. The commissioner's office will publish a summary of this analysis, which may contain legislative recommendations aimed at improving the reimbursement process, considering the potential costs to consumers, health insurers, providers, and the state. The findings and recommendations are to be reported to the general assembly by February 28, 2026. The act will take effect on January 1, 2025.